Purdue Pharma’s federal sentencing finalizes a landmark opioid case involving fraud and kickback conspiracies, with lasting compliance implications for the pharmaceutical supply chain.
Purdue Pharma’s federal sentencing finalizes a landmark opioid case involving fraud and kickback conspiracies, with lasting compliance implications for the pharmaceutical supply chain.
A leading pharmaceutical trade group has filed a federal lawsuit challenging Washington state’s new 340B law, arguing it unlawfully interferes with manufacturer control over drug distribution and pricing requirements.
A leading pharmaceutical trade group has filed a federal lawsuit challenging Washington state’s new 340B law, arguing it unlawfully interferes with manufacturer control over drug distribution and pricing requirements.
A new executive order directs federal agencies to accelerate the development, review, and potential patient access to investigational psychedelic therapies for serious mental illness, signaling a shift in regulatory and research priorities...
A new executive order directs federal agencies to accelerate the development, review, and potential patient access to investigational psychedelic therapies for serious mental illness, signaling a shift in regulatory and research priorities...
The Centers for Medicare & Medicaid Services has proposed sweeping reforms to modernize prior authorization for drugs, introducing faster decision timelines, expanded electronic requirements, and new transparency measures that could...
The Centers for Medicare & Medicaid Services has proposed sweeping reforms to modernize prior authorization for drugs, introducing faster decision timelines, expanded electronic requirements, and new transparency measures that could...
The US Department of Justice (DOJ) has launched sweeping enforcement actions targeting over $500 million in alleged fraud across Affordable Care Act (ACA) enrollment, Medicaid drug billing, and COVID-19 relief programs, highlighting...
The US Department of Justice (DOJ) has launched sweeping enforcement actions targeting over $500 million in alleged fraud across Affordable Care Act (ACA) enrollment, Medicaid drug billing, and COVID-19 relief programs, highlighting...
The Federal Trade Commission (FTC) has paused its case against Caremark to consider a proposed settlement, signaling a potential early resolution in its broader enforcement action against pharmacy benefit managers (PBMs) while litigation...
The Federal Trade Commission (FTC) has paused its case against Caremark to consider a proposed settlement, signaling a potential early resolution in its broader enforcement action against pharmacy benefit managers (PBMs) while litigation...
Two wholesale pharmaceutical executives were sentenced in a large-scale drug diversion case that raised concerns about medication safety and supply chain integrity.
Two wholesale pharmaceutical executives were sentenced in a large-scale drug diversion case that raised concerns about medication safety and supply chain integrity.
Novo Nordisk has dropped its patent lawsuit against Hims & Hers after the telehealth company agreed to stop promoting compounded GLP-1 products and instead offer US Food and Drug Administration (FDA)-approved Ozempic and Wegovy at established...
Novo Nordisk has dropped its patent lawsuit against Hims & Hers after the telehealth company agreed to stop promoting compounded GLP-1 products and instead offer US Food and Drug Administration (FDA)-approved Ozempic and Wegovy at established...
Louisiana secured a $45 million settlement from CVS and its pharmacy benefit manager (PBM) affiliate following lawsuits alleging deceptive practices, misuse of patient data, and anti-competitive conduct affecting independent pharmacies.
Louisiana secured a $45 million settlement from CVS and its pharmacy benefit manager (PBM) affiliate following lawsuits alleging deceptive practices, misuse of patient data, and anti-competitive conduct affecting independent pharmacies.
A federal judge has preliminarily approved a $5.275 million nationwide settlement resolving claims that PharMerica failed to safeguard patient data in a 2023 ransomware attack.
A federal judge has preliminarily approved a $5.275 million nationwide settlement resolving claims that PharMerica failed to safeguard patient data in a 2023 ransomware attack.
